Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1959 1
1994 2
1995 5
1996 4
1997 2
1998 1
1999 6
2000 3
2001 6
2002 6
2003 3
2004 3
2005 5
2006 7
2007 12
2008 12
2009 13
2010 20
2011 35
2012 30
2013 13
2014 17
2015 18
2016 20
2017 27
2018 29
2019 18
2020 15
2021 16
2022 20
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

329 results

Results by year

Filters applied: . Clear all
Page 1
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Routy B, et al. Among authors: goldwasser f. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2. Science. 2018. PMID: 29097494
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, Drubay D, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, Besse B. Derosa L, et al. Among authors: goldwasser f. Nat Med. 2022 Feb;28(2):315-324. doi: 10.1038/s41591-021-01655-5. Epub 2022 Feb 3. Nat Med. 2022. PMID: 35115705 Free PMC article.
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Henry DH, et al. Among authors: goldwasser f. J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343556 Clinical Trial.
Individualized Pazopanib Dosing-Letter.
Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M, Goldwasser F, Blanchet B. Bellesoeur A, et al. Among authors: goldwasser f. Clin Cancer Res. 2017 Oct 15;23(20):6377. doi: 10.1158/1078-0432.CCR-17-1873. Clin Cancer Res. 2017. PMID: 29030334 No abstract available.
Resting energy metabolism and anticancer treatments.
Jouinot A, Vazeille C, Goldwasser F. Jouinot A, et al. Among authors: goldwasser f. Curr Opin Clin Nutr Metab Care. 2018 May;21(3):145-151. doi: 10.1097/MCO.0000000000000457. Curr Opin Clin Nutr Metab Care. 2018. PMID: 29369114 Review.
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Among authors: goldwasser f. Clin Pharmacokinet. 2019 Apr;58(4):451-467. doi: 10.1007/s40262-018-0703-0. Clin Pharmacokinet. 2019. PMID: 30094711 Review.
Drug interactions with solid tumour-targeted therapies.
Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F. Thomas-Schoemann A, et al. Among authors: goldwasser f. Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041628 Review.
Supplemental parenteral nutrition in cancer care: why, who, when.
Cotogni P, Bozzetti F, Goldwasser F, Jimenez-Fonseca P, Roelsgaard Obling S, Valle JW. Cotogni P, et al. Among authors: goldwasser f. Ther Adv Med Oncol. 2022 Sep 26;14:17588359221113691. doi: 10.1177/17588359221113691. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36188487 Free PMC article. Review.
329 results